Changes in the Management of Common Bile Duct Stones: 1980 to Date
Department of Medicine (retired), Hadassah University Hospital, Jerusalem, Israel
*To whom correspondence should be addressed. E-mail: jochanan.benbassat@gmail.comAbstract
Objective
To compare the results of treating patients with common bile duct (CBD) stones by endoscopic sphincterotomy (ES), surgical exploration, or a combination of ES and surgical CBD exploration (the rendezvous technique).
Methods
A narrative review of the literature.
Summary of Data
Before 1990, 17 cohort studies indicated that ES cleared CBD stones in 92.0% of patients, with a mortality rate of 1.5%. Surgery removed CBD stones in 90.2% of patients, with a 2.1% mortality rate. A single randomized controlled trial in 1987 showed that ES removed CBD stones in 91% of 55 patients, with a 3.6% mortality rate and a 27% complication rate, whereas surgical CBD exploration removed CBD stones in 92%, with a 1.8% mortality rate and a 22% complication rate. Since 1991, 26 randomized controlled trials have shown that laparoscopic–ES rendezvous is as effective as ES alone and laparoscopic surgery alone but is associated with fewer complications, a reduced need for additional procedures, and a shorter hospital stay.
Conclusions
A laparoscopic–ES rendezvous appears to be the optimal approach to the treatment of CBD stones in younger and fit patients. The choice between ES alone and laparoscopic–ES rendezvous in older or high-risk patients remains uncertain.
INTRODUCTION
The alternative approaches to the management of patients with common bile duct (CBD) stones include open surgical choledochotomy, endoscopic sphincterotomy, and laparoscopic CBD exploration. Open choledochotomy requires anesthesia and abdominal surgery. Endoscopic sphincterotomy (ES) entails upper endoscopy, identification of the ampulla of Vater, and clearance of the CBD stones after sphincterotomy. Since it was described in 1974, ES is an established technique for CBD stone removal.1 Laparoscopic CBD exploration was first employed in the 1990s. It is as safe and efficient as open surgery, provides a clearer vision, and is associated with less pain and quicker recovery.2 As many as 26% of the patients who were discharged with gallbladders in situ after CBD clearance required follow-up cholecystectomy for biliary symptoms.3 Therefore, it is considered best practice to combine CBD clearance with cholecystectomy.
Endoscopic sphincterotomy may be complicated by failure to cannulate the ampulla of Vater and pancreatitis that can follow inadvertent pancreatic cannulation and contrast injection. Hence the advantage of the simultaneous clearance of CBD stones by ES during laparoscopic surgery (laparoscopic–ES rendezvous).4 The laparoscopic–ES rendezvous procedure is a single-stage laparoscopic and endoscopic approach to CBD treatment that minimizes the risk of inadvertent pancreatic duct cannulation and pancreatitis, thereby leading to a shorter hospital stay, higher success rate, and lower cost. It entails laparoscopic incision of the cystic duct by a first team of surgeons; introduction of a radiopaque guiding catheter toward the duct; intraoperative cholangiography to confirm biliary stones; and introduction of a guidewire through the biliary tree into the duodenum under radiological guidance. This guidewire helps the endoscopic identification of the ampulla of Vater by a second team who also clears the CBD stones.
The choice between these alternatives depends on the severity of the symptoms, the presence of the gallbladder, and local expertise. Endoscopic sphincterotomy has gained acceptance in the treatment of patients with retained CBD stones after cholecystectomy and in high-risk patients with intact gallbladders. Its role in the treatment of younger and fit patients is uncertain. In 1980–1990, this uncertainty led to different management of CBD stones: in the United States, only 15% of the patients with intact gallbladders and biliary symptoms had ES; in Europe, this figure exceeded 60%.5 The choice between laparoscopic–ES rendezvous and preoperative ES is similarly uncertain. A 2018 Cochrane Review of five randomized trials concluded that there was insufficient evidence to determine this choice because the quality of evidence was low.6
The aim of the present study is, first, to review the changes in the treatment of patients with CBD stones since 1980; and, second, to compare the results of ES alone, surgical (open and laparoscopic) CBD exploration, and laparoscopic–ES rendezvous to determine the optimal approach for the treatment of patients with CBD stones.
METHODS
This is not a systematic review. We searched a single database (Google Scholar) for reports published in English since 1970 on combinations of the following terms: choledocholithiasis, cholecystectomy, common bile duct calculi, randomized trials, and choledocholithiasis. Additional studies were sought by screening the bibliographies of review articles. We included uncontrolled cohort studies published before 1990 and randomized trials since 1990. We excluded reports of patients with previously attempted CBD stone clearance, malignant biliary disorders, and those that compared the timing of cholecystectomy after ES. The number of patients with CBD stones in the reported series was the denominator for calculations of the success rate in clearing CBD stones, while the total number of patients entered into the trial, including those with suspected but absent CBD stones, was the denominator for complications and mortality.
DATA SYNTHESIS
Table 1 summarizes uncontrolled cohort studies published before 1990; Tables 2 and 3 present their results in more detail. Endoscopic sphincterotomy cleared CBD stones in 92.0%, with a mortality of 1.5%, complications in 8.2%, and a need for additional treatment in 3.3%. The most common complications after ES were hemorrhage and duodenal perforation after cutting the papilla, and acute pancreatitis and cholangitis after injection of the contrast media.7 Before 1990, open surgical CBD exploration cleared CBD stones in 90.2% of the patients. Mortality was 2.1%, and complications occurred in 18.3%. Reoperations, needed in 6.5% of the patients, were most commonly for recurrent/retained stones, stenosis of the ampulla, and pancreatitis.8 In both ES and surgical CBD exploration, complications and mortality increased with age.
| Years | Intervention | Patients n | Stone Clearance n (%)* | Additional CBDI needed (ES or Surg.) n (%)† | Complications n (%)† | Mortality n (%) | Length of Hospital Stay d (range) |
|---|---|---|---|---|---|---|---|
| 1982–1989 | ES | 3,818 | 2,210/2,403 (92.0) | 110/3,306 (3.3) | 312/3,798 (8.2) | 56/3,818 (1.5) | 3–6 |
| 1972–1990 | Surg. | 3,606 | 1,952/2,164 (90.2) | 155/2,391 (6.5) | 575/3,142 (18.3) | 77/3,606 (2.1) | 10–16 |
| Author | Mean age y | Patients n | Stone Clearance n (%)* | Additional CBDI Needed (ES or Surg.) n (%)† | Complications n (%)† | Mortality n (%) | Length of Hospital Stay d (range) |
|---|---|---|---|---|---|---|---|
| Cotton (1982)18 | 75.0 | 71 | 61/71 (85.9) | 2/71 (2.8) | 2/71 (2.8) | 1/71 (1.4) | NG |
| Danilewitz (1984)11 | 61.9 | 53 | 48/53 (90.6) | NG | 5/53 (9.4) | 0/53 (0.0) | NG |
| Escourrou et al. (1984)21 | 79.0 | 443 | 428/443 (91.2) | 7/443 (1.6) | 27/443 (6.1) | 6/443 (1.4) | NG |
| Neoptolemos et al. (1984)20 | 78.0 | 100 | 91/100 (91.0) | 5/100 (5.0) | 13/100 (13.0) | 1/100 (1.0) | NG |
| Roberts-Thomson (1984)12 | 63.0 | 300 | 147/164 (90.0) | 5/300 (1.7) | 14/300 (4.7) | 0/300 (0.0) | NG |
| Leow and Thompson (1986)22 | 79.5 | 20 | 16/20 (80.0) | NG | NG | 0/20 (0.0) | NG |
| Duron et al. (1987)25 | 83.0 | 33 | 25/26 (96.2) | 1/33 (3.0) | 0/33 (0.0) | 2/33 (6.1) | NG |
| Neoptolemos et al. (1987)19 | 75.7 | 190 | 156/190 (82.1) | 19/190 (10.0) | 33/190 (17.4) | 15/190 (7.9) | NG |
| Davidson (1988)17 | 79.0 | 106 | 98/106 (97.1) | 6/106 (5.7) | 21/106 (19.8) | 12/106 (11.3) | NG |
| Ikeda et al. (1988)13 | 65.0 | 469 | 438/469 (93.4) | NG | 30/469 (6.4) | 2/469 (0.4) | NG |
| Miller et al. (1988)14 | 68.0 | 156 | 133/156 (85.3) | 18/156 (11.5) | 22/156 (14.1) | 5/156 (3.2) | 6.0 |
| Siegel et al. (1988)5 | 73.3 | 1272 | NG | 25/1272 (2.0) | 109/1272 (8.6) | 2/1272 (0.2) | NG |
| Hansell et al. (1989)24 | 80.0 | 121 | 115/121 (95.0) | 4/121 (3.3) | 5/121 (4.1) | 6/121 (5.0) | NG |
| Heinerman et al. (1989)10 | 56.3 | 190 | 189/190 (99.5) | 1/190 (0.5) | 4/190 (2.1) | 0/190 (0.0) | NG |
| Ingoldby et al. (1989)23 | 79.7 | 186 | 172/186 (92.5) | 4/186 (2.2) | 9/186 (4.8) | 3/186 (1.6) | 3.7 |
| Worthley (1989)16 | 73.0 | 50 | 44/50 (88.0) | 7/50 (14.0) | 12/50 (24.0) | 0/50 (0.0) | 3.0 |
| Miller and Ferguson (1990)15 | NG | 58 | 52/58 (90.0) | 6/58 (10.3) | 6/58 (10.3) | 1/58 (1.7) | 3.6 |
| Total | 56–83 | 3818 | 2210/2403 (92.0) | 110/3306 (3.3) | 312/3798 (8.2) | 56/3818 (1.5) | 3–6 |
| Author | Mean age y | Patients n | Stone Clearance n (%)* | Additional CBDI Needed (ES or Surg.) n (%)† | Complications n (%)† | Mortality n (%) | Length of Hospital Stay d (range) |
|---|---|---|---|---|---|---|---|
| Way et al. (1972)29 | 56.9 | 200 | 127/141 (90.1) | 22/200 (11.0) | NG | 5/200 (2.5) | NG |
| Stefanini et al. (1974)28 | 56.6 | 712 | NG | NG | 14/712 (2.0) | 7/712 (1.1) | NG |
| Vellacott and Powel (1979)35 | 66 | 122 | 71/78 (92.2) | NG | 11/122 (9.0) | 9/122 (7.4) | 16 |
| Gaskill et al. (1982)27 | 56 | 71 | 64/71 (90.1) | NG | 21/71 (29.6) | 2/71 (2.8) | 13 |
| Antrum and Hall (1984)34 | 60.8 | 118 | 101/118 (85.6) | 4/118 (3.4) | 7/118 (5.9) | 3/118 (2.5) | 12 |
| Crumplin et al. (1985)33 | 60.4 | 160 | 84/95 (88.4) | 5/160 (3.1) | 73/160 (45.6) | 4/160 (2.5) | 16.2 |
| Rogers et al. (1985)32 | 60 | 100 | 46/55 (83.6) | 3/100 (3.0) | NG | 3/100 (3.0) | NG |
| Roukema et al (1986)37 | <70 | 657 | 514/557 (92.3) | 42/1007 (4.2) | 203/1007 (20.2) | 6/657 (0.9) | NG |
| 70–79 | 266 | 7/266 (2.6) | |||||
| >80 | 84 | 8/84 (9.5) | |||||
| Neoptolemos et al. (1987)9 | 57.9 | 248 | 212/238 (89.1) | 26/248 (10.5) | 56/248 (22.6) | 10/248 (4.0) | NG |
| Sheridan et al. (1987)30 | 57.4 | 257 | 163/200 (81.5) | 22/257 (8.6) | 118/257 (45.9) | 5/257 (1.9) | 15.6 |
| Irvin and Arnstein (1988)36 | <70 | 77 | 75/77 (97.4) | NG | 5/77 (7.0) | 0/77 (0.0) | 10.4 |
| >70 | 69 | 66/69 (95.7) | NG | 12/69 (17.4) | 2/69 (2.9) | 13.4 | |
| Miller et al. (1988)14 | 58.0 | 81 | 76/81 (93.8) | 5/81 (6.2) | 13/81 (16.0) | 1/81 (1.2) | 10.3 |
| Heinerman et al. (1989)10 | 56.3 | 78 | 65/78 (83.3) | 12/78 (15.4) | 17/78 (21.8) | 3/78 (3.8) | NG |
| McEntee et al. (1989)31 | 59.4 | 164 | 160/164 (97.6) | NG | NG | 1/164 (0.6) | NG |
| Miller and Ferguson (1990)15 | NG | 42 | 33/42 (78.6) | 9/42 (21.4) | 10/42 (23.8) | 1/42 (2.4) | 10.4 |
| Pappas et al. (1990)26 | 52.7 | 100 | 95/100 (95.0) | 5/100 (5.0) | 15/100 (15.0) | 0/100 (0.0) | NG |
| Total | 52–>80 | 3606 | 1952/2164 (90.2) | 155/2391 (6.5) | 575/3142 (18.3) | 77/3606 (2.1) | 10.3–16 |
Table 4 summarizes the outcomes of the 26 randomized controlled trials that we could identify in the literature since Neoptolemos et al.9 published the first one in 1987, and Tables 5, 6, and 7 present their results in more detail. Before 2000, six of nine trials indicated that ES was associated with either a lower clearance of CBD stones or a higher mortality than open surgical CBD exploration. The remaining three studies indicated that ES and surgical treatment were equally effective (Table 5). In 2001–2010, five of eight trials showed that ES and laparoscopic surgery were equally safe and effective. In three studies, laparoscopic–ES rendezvous prevented post-ES pancreatitis and was associated with shorter hospital stays and less morbidity than ES alone (Table 6). Since 2011, four of nine trials found that laparoscopic surgery was preferred as it avoids cholangitis, papillary stenosis, or pancreatitis after ES, with less morbidity and earlier recovery. One of nine trials indicated that ES alone and laparoscopic surgery alone were equally safe and effective. The remaining four studies confirmed that laparoscopic–ES rendezvous prevents post-ES pancreatitis and is associated with shorter hospital stays (Table 7).
| Years | Intervention | Patients n | Stone Clearance n (%)* | Additional CBDI needed (ES or Surg.) n (%)† | Complications n (%)† | Mortality n (%) | Length of Hospital Stay d (range) |
|---|---|---|---|---|---|---|---|
| 1980–2000 | ES | 472 | 301/358 (84.1) | 70/472 (14.8) | 73/472 (15.5) | 10/472 (2.1) | 3.5–17 |
| Surg. | 313 | 201/220 (91.4) | 37/265 (14.0) | 60/313 (19.2) | 4/313 (1.3) | 6–22 | |
| Lap. | 173 | 130/149 (87.2) | 29/149 (19.5) | 28/173 (16.2) | 1/173 (0.6) | 1–6 | |
| 2001–2010 | ES | 421 | 274/353 (77.6) | 42/421 (9.8) | 55/421 (13.1) | 1/421 (0.2) | 3–9 |
| Lap. | 293 | 217/239 (90.8) | 26/293 (8.9) | 31/293 (10.6) | 1/293 (0.3) | 4–8 | |
| Lap.–ES | 165 | 123/131 (93.9) | 9/165 (5.5) | 8/165 (4.8) | 0/165 (0) | 3–5 | |
| 2011–2023 | ES | 637 | 496/553 (89.7) | 28/433 (6.5) | 62/596 (10.4) | 3/637 (0.5) | 3–11 |
| Lap. | 528 | 423/449 (94.2) | 22/366 (6.0) | 42/528 (8.0) | 0/528 (0) | 2–7 | |
| Lap.–ES | 220 | 155/167 (92.8) | 3/79 (3.8) | 8/178 (4.5) | 1/220 (0.5) | 1–7 | |
| Author | Intervention | Mean Age y (range or ±SD) | Patients n | Stone Clearance n (%)* | Additional CBDI needed (ES or Surg.) n (%)† | Minor and Major Complications n (%)† | Mortality n (%) | Length of Hospital Stay d (mean or mean range) | Author Conclusions |
|---|---|---|---|---|---|---|---|---|---|
| Neoptolemos et al. (1987)9 | ES | 61 (20–83) | 55 | 50/55 (91.0) | 2/55 (2.8) | 18/55 (32.7) | 2/55 (3.6) | 9 | No support for ES for CBD stones |
| Surg. | 59 (20–82) | 59 | 54/59 (91.5) | 0/59 (0.0) | 13/59 (22.1) | 1/59 (1.7) | 11 | ||
| Stain et al. (1991)38 | ES | 48.4 (31–78) | 26 | 17/26 (65.4) | 1/26 (3.1) | 4/26 (15.4) | 0.0 | 5 | No support for ES for CBD stones |
| Surg. | 42.4 (20–86) | 26 | 16/17 (84.2) | 1/17 (3.1) | 8/26 (30.8) | 0.0 | 6 | ||
| Stiegmann et al. (1992)39 | ES | 46.3±21.7 | 16 | 5/7 (71.4) | 2/7 (28.6) | 0 (0.0) | 0.0 | 11.0 | No advantage to treating CBD stones with ES |
| Surg. | 38.1±14.8 | 18 | 6/7 (85.7) | Not given | 3/18 (16.7) | 0.0 | 9.2 | ||
| Hammarström et al. (1995)40 | ES | 75.0 (56–85) | 39 | 35/39 (89.7) | 7/39 (17.9) | 7/39 (17.9) | 0.0 | 13‡ | ES and Surg. for CBD stones are equally effective |
| Surg. | 73.5 (56–85) | 41 | 37/41 (90.2) | 6/41 (14.6) | 9/41 (22.0) | 0.0 | 16‡ | ||
| Kapoor et al. (1996)42 | ES | 42 (20–60) | 13 | 11/13 (85) | 2/13 (15) | 5/13 (38.5) | 0 (0.0) | 10.6 | No support for ES in low-risk patients with CBD |
| Surg. | 46 (24–75) | 16 | 13/15 (87) | 2/15 (13) | 5/16 (31.3) | 0 (0.0) | 11.3 | ||
| Targarona et al. (1996)41 | ES | 79 | 50 | NG | 2/50 (4.0) | 8/50 (16) | 3/50 (6.0) | 17 | In elderly or high-risk patients, surgery is preferable to ES |
| Surg. | 80 | 48 | NG | 1/48 (2.1) | 11/48 (23) | 2/48 (4.0) | 22 | ||
| Rhodes et al. (1998)44 | ES | 68 (28–84) | 40 | 37/40 (92.5) | 10/40 (25.0) | 6/40 (15.0) | 0 (0.0) | 3.5‡ | Lap. is as effective as ES in clearing CBD stones |
| Lap. | 62 (24–83) | 40 | 40/40 (100) | 10/40 (25.0) | 7/40 (17.5) | 0 (0.0) | 1‡ | ||
| Suc et al. (1998)43 | ES | 66.8±17.5 | 97 | 64/80 (80.0) | 28/97 (28.9) | 11/97 (11.3) | 3/97 (3.1) | 15.3 | High risk of added procedures after ES precludes its use for treating CBD stones |
| Surg. | 66.7±18.1 | 105 | 75/81 (92.6) | 8/105 (7.6) | 13/105 (12.3) | 1/105 (1.0) | 17.5 | ||
| Cuschieri et al. (1999)45 | ES | 18–89 | 136 | 82/98 (83.7) | 16/98 (16.3) | 17/133 (12.8) | 2/136 (1.5) | 9‡ | Similar outcomes for ES and Lap., shorter hospital stay with Lap. ES to be confined to high-risk patients |
| Lap. | 19–88 | 133 | 90/109 (82.6) | 19/109 (17.4) | 21/133 (15.8) | 1/133 (0.8) | 6‡ | ||
| Total | ES | 472 | 301/358 (84.1) | 70/472 (14.8) | 73/472 (15.5) | 10/472 (2.1) | 3.5–17 | ||
| Surg. | 313 | 201/220 (91.4) | 37/265 (14.0) | 60/313 (19.2) | 4/313 (1.3) | 6–22 | |||
| Lap. | 173 | 130/149 (87.2) | 29/149 (19.5) | 28/173 (16.2) | 1/173 (0.6) | 1–6 | |||
| Author | Intervention | Mean Age y (range or SD) | Pts. n | Stone Clearance n (%)* | Additional CBDI needed (ES or Surg.) n (%)† | Minor and Major Complications n (%)† | Mortality n (%) | Length of Hospital Stay d (mean or mean range) | Author Conclusions |
|---|---|---|---|---|---|---|---|---|---|
| Sgourakis and Karaliotas (2002)46 | ES | 46–89 | 42 | 27/32 (84.3) | 5/42 (11.9) | 6/42 (14.3) | 1/42 (2.4) | 9.0 | There is a need for further randomized trials |
| Lap. | 43–88 | 36 | 24/28 (85.7) | 4/36 (11.1) | 5/36 (13.9) | 1/36 (2.8) | 7.4 | ||
| Hong et al. (2006)47 | ES | Not given | 93 | 85/93 (91.4) | 8/93 (8.6) | 9/93 (9.4) | 0 (0.0) | 4.3 | ES and Lap. are safe and effective treatments for CBD stones |
| Lap. | 48 (15–82) | 141 | 126/141 (89.4) | 15/141 (10.6) | 8/141 (5.6) | 0 (0.0) | 4.7 | ||
| Lella et al. (2006)52 | ES | Not given (<60) | 60 | 58/60 (96.7) | 0/60 (0.0) | 8/60 (13.3) | 0 (0.0) | 6 | Lap.-ES prevents post-ES pancreatitis in patients at risk for this complication |
| Lap.-ES | Not given (<60) | 60 | 59/60 (98.3) | 2/60 (3.3) | 2/60 (3.3) | 0 (0.0) | 3 | ||
| Morino et al. (2006)4 | ES | 63.1 (25–83) | 45 | 9/45 (80.0) | 17/45 (37.8) | 3/45 (6.6) | 0 (0.0) | 8.0 | Lap.-ES carries a higher rate of CBD stones clearance and shorter hospital stays than ES |
| Lap.-ES | 56.6 (22–82) | 46 | 44/46 (95.6) | 3/46 (6.5) | 3/46 (6.5) | 0 (0.0) | 4.3 | ||
| Rábago et al. (2006)51 | ES | Not given (<80) | 64 | 28/31 (90.5) | 7/64 (10.9) | 12/64 (18.8) | 0 (0.0) | 8 | Lap.-ES had less morbidity and a shorter hospital stay than ES |
| Lap.-ES | Not given (<80) | 59 | 20/25 (80.0) | 4/59 (6.8) | 3/59 (5.1) | 0 (0.0) | 5 | ||
| Noble et al. (2009)48 | ES | 74.3 (70–79) | 47 | 26/46 (56.5) | 2/47 (4.3) | 8/47 (17.0) | 0 (0.0) | 3 | No difference in hospital stay, complications, or conversion. Lap. was more effective and avoided unnecessary procedures |
| Lap. | 75.9 (70–81) | 44 | 38/38 (100) | 4/44 (9.1) | 8/44 (18.2) | 0 (0.0) | 5 | ||
| Bansal et al. (2010)50 | ES | 39.1 (23–64) | 15 | 11/15 (73.3) | 2/15 (13.3) | 4/15 (26.7) | 0 (0.0) | 4.0 | Equivalent morbidity and hospital stay. Lap. carried a smaller number of procedures |
| Lap. | 47.1 (34–72) | 15 | 14/15 (93.3) | 1/15 (6.7) | 4/15 (26.7) | 0 (0.0) | 4.2 | ||
| Rogers et al. (2010)49 | ES | 44.6±1.9 | 55 | 30/31 (98) | 1/55 (1.8) | 5/55 (9.1) | 0 (0.0) | 6.6 | ES and Lap. are highly effective in treating CBD stones. Hospital stay was shorter for Lap. |
| Lap. | 39.9±1.9 | 57 | 15/17 (88) | 2/57 (3.5) | 6/57 (10.5) | 0 (0.0) | 5.3 | ||
| Total | ES | 421 | 274/353 (77.6) | 42/421 (9.8) | 55/421 (13/1) | 1/421 (0.2) | 3–9 | ||
| Lap. | 293 | 217/239 (90.8) | 26/293 (8.9) | 31/293 (10.6) | 1/293 (0.3) | 4.2–7.4 | |||
| Lap.-ES | 165 | 123/131 (93.9) | 9/165 (5.5) | 8/165 (4.8) | 0/165 (0.0) | 3–5 | |||
| Author | Intervention | Mean Age y (range or SD) | Patients n | Stone Clearance n (%)* | Additional CBDI Needed (ES or Surg.) n (%)† | Complications n (%)† | Mortality n (%) | Length of Hospital Stay d (mean or mean range) | Author Conclusions |
|---|---|---|---|---|---|---|---|---|---|
| ElGeidie et al. (2011)53 | ES | 29.2 (20–67) | 111 | 98/107 (91.6) | 7/111 (6.3) | 10/111 (9.3) | 0 (0.0) | 3.1 | ES and Lap. safe and effective treatments for CBD stones |
| Lap. | 32.5 (19–64) | 115 | 104/110 (94.5) | 9/115 (7.8) | 8/115 (7.0) | 0 (0.0) | 2.2 | ||
| Ferulano et al. (2011)54 | ES | 55±15 | 62 | 37/39 (95) | Not given | 6/62 (9.7) | 0 (0.0) | 3.5 | Lap. avoids cholangitis, papillary stenosis, or pancreatitis after ES |
| Lap. | 53±13 | 62 | 42/45 (93) | Not given | 4/62 (6.5) | 0 (0.0) | 7.1 | ||
| Tzovaras et al. (2012)59 | ES | 69 (25–85) | 49 | 39/49 (79.6) | 1/49 (2.0) | 6/49 (12.2) | 0 (0.0) | 5.5 | Lap.-ES carries less hospital stay and lower amylase levels than ES |
| Lap.-ES | 66 (22–87) | 50 | 44/50 (88.0) | 2/50 (4.0) | 7/50 (14) | 1/50 (2.0) | 4 | ||
| Koc et al. (2013)55 | ES | 54.9±17.9 | 54 | 51/54 (94.4) | 1/54 (1.9) | 6/54 (11.1) | 0 (0.0) | 6 | Lap. has less morbidity and allows earlier recovery than ES |
| Lap. | 51.5±16.6 | 57 | 55/57 (96.5) | 0/57 (0.0) | 4/57 (7.0) | 0 (0.0) | 3 | ||
| Bansal et al. (2014)56 | ES | 45.1±15.1 | 84 | 73/83 (88.0) | 16/84 (19.1) | 19/84 (22.6) | 3/84 (3.7) | 5.3 | Lap. has shorter hospital stays and needs fewer procedures |
| Lap. | 43.0±13.7 | 84 | 77/84 (91.7) | 10/84 (11.9) | 20/84 (23.8) | 0 (0.0) | 4.6 | ||
| Ding et al. (2014)57 | ES | 57.5±6.3 | 111 | 105/111 (94.6) | 1/111 (0.9) | 6/111 (5.4) | 0 (0.0) | NG | Lap. is the treatment of choice for patients with CBD stones |
| Lap. | 58.4±7.2 | 110 | 103/110 (93.6) | 3/110 (2.7) | 4/110 (3.6) | 0 (0.0) | NG | ||
| Sahoo et al. (2014)60 | ES | 48 (21–75) | 41 | 29/41 (70.7) | NG | NG | 0 (0.0) | 10.9 | Lap.-ES reduces pancreatitis, hospital stays, and interventions |
| Lap.-ES | 48 (21–75) | 42 | 38/42 (90.5) | NG | NG | 0 (0.0) | 6.8 | ||
| Barreras González et al. (2016)61 | ES | 57.7 (20–84) | 101 | 42/45 (93.3) | Not given | 6/101 (5.9) | 0 (0.0) | 3.1 | Lap.-ES shows a higher rate of CBD stone clearance, a shorter hospital stay, and lower morbidity |
| Lap. | 56.3 (22–87) | 100 | 42/43 (97.7) | Not given | 2/100 (2.0) | 0 (0.0) | 2.1 | ||
| Lap.-ES | 58.4 (23–87) | 99 | 45/46 (97.8) | Not given | 0/99 (0.0) | 0 (0.0) | 1.2 | ||
| Lv et al. (2016)58 | ES | 63.5±12.4 | 24 | 22/24 (91.7) | 2/24 (8.3) | 3/24 (12.5) | 0 (0.0) | 10.9 | Lap.-ES resulted in a shorter hospital stay |
| Lap.-ES | 61.3±14.5 | 29 | 28/29 (96.6) | 1/29 (3.4) | 1/29 (3.4) | 0 (0.0) | 6.7 | ||
| Total | ES | 637 | 496/553 (89.7) | 28/433 (6.5) | 62/596 (10.4) | 3/637 (0.5) | 3.1–10.9 | ||
| Lap. | 528 | 423/449 (94.2) | 22/366 (6.0) | 42/528 (8.0) | 0/528 (0.0) | 2.1–7.1 | |||
| Lap.-ES | 220 | 155/167 (92.8) | 3/79 (3.8) | 8/178 (4.5) | 1/220 (0.5) | 1.2–6.8 | |||
CONCLUSIONS
Three main findings emerge from the present review: first, as expected, since 1990, there has been a uniform decline in mortality, complications, and the need for added interventions in the treatment of choledocholithiasis by ES and laparoscopic CBD exploration. Second, since 2001, the differences in mortality (0% and 0.5%) and stone clearance (89.7% and 94.2%) between ES and laparoscopic CBD exploration were negligible. Third, laparoscopic–ES rendezvous was associated with fewer additional interventions, fewer complications, and shorter hospital stays.
Therefore, the combined approach (laparoscopic–ES rendezvous) seems to be the preferred one for the treatment of patients with choledocholithiasis. Unfortunately, this requires a high degree of collaboration between departments in those environments where this procedure is done by different services, and therefore cannot be performed in environments with low resources.
The first limitation of the presented review is its failure to assess the quality of the evidence and the risk of bias in the individual studies. Second, since the presented review is not systematic, it is possible that we missed relevant studies. Still, the consistency of our findings over the last two decades supports their validity. Therefore, we conclude that, given experience and facilities, the laparoscopic–ES rendezvous is preferable over ES alone or laparoscopic surgery alone. The combined approach obviates the need to cut the papilla, thereby preventing hemorrhage and perforation, and improves the selective cannulation of the CBD, thereby preventing inadvertent cannulation of the pancreatic duct with the injection of contrast media into it and pancreatitis.62
Should ES alone be confined only to patients with retained CBD stones after cholecystectomy, and to high-risk patients with CBD stones and intact gallbladders? We know of no comparative studies of the outcome of ES alone and the rendezvous technique by patients’ age. Therefore, we believe that the role of the laparoscopic–ES rendezvous procedure in the treatment of high-risk patients with CBD stones remains uncertain. It should be the subject of future trials that will probably address also cost.
Abbreviations
- CBD
- common bile duct
- ES
- endoscopic sphincterotomy
- Surg.
- surgical common duct exploration